Compare Abeona Therapeutics Inc (ABEO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tesla, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Tesla, Inc. trades at $392.32 (market cap $1.51T). The key difference: Tesla, Inc. is far larger — about 4044.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | TSLA | |
|---|---|---|
Market Cap | $373.32M | $1.51T |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $489.88 |
52-Week Low | $4.17 | $295.88 |
Enterprise Value | $228.22M | $1.48T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Tesla (TSLA) trades at $395.04, down 5.89% over the past 24 hours, with a neutral technical signal and mixed earnings history. The stock shows elevated valuation ratios (P/E 369.63, P/S 14.54) against declining profitability margins (net income margin 3.95% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, while Q1 2026 deliveries missed estimates amid competitive pressures.
Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include softening auto demand and high valuation. Analyst consensus price target is $429.91, implying upside, yet sentiment is cautious with 39.51% buy ratings. Investors face volatility from execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
